CJC-1295 No DAC: Dosage, Half-Life and What It Is
CJC-1295 no DAC (mod GRF 1-29): the short-acting form, its common daily protocol, and how it differs from the with-DAC version.
The short version
CJC-1295 without DAC, sold as "mod GRF 1-29", lacks the albumin-binding linker that makes the with-DAC form last for days. Sources describe it clearing much faster, so the common protocol is a daily injection rather than a weekly one. No published human pharmacokinetic study establishes its half-life, and no trial has established a dose. What follows is common research-channel practice.
- No DAC (mod GRF 1-29) lacks the albumin-binding linker that the with-DAC form has. It is a real structural difference, not a marketing label.
- The common daily protocol is 100-300 mcg, subcutaneous, once daily, 5 days on/2 off.
- No published human pharmacokinetic study establishes a half-life for this form. The "~30 minutes" figure circulating online is unverified.
- The with-DAC form is dosed weekly instead. See the DAC page; the two protocols are not interchangeable.
“CJC-1295 no DAC” and “CJC-1295” (with DAC) are sold under variations of one name but are not the same product. This page covers the no-DAC form, sold as “mod GRF 1-29”, and its own daily protocol. For the with-DAC form’s weekly dosing, see CJC-1295 DAC. For the full with-DAC/without-DAC distinction and the evidence behind each, see the main CJC-1295 guide. For the published trial data behind the with-DAC form, see CJC-1295 dosage.
US legal status - Research use only
CJC-1295 has no FDA-approved product in either form, and no approved indication or dose.
AU legal status - Not on the ARTG
Schedule 4 of the Poisons Standard and named under Appendix D - prescription only, and not on the ARTG.
Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.
What is CJC-1295 no DAC?
CJC-1295 without DAC lacks the Drug Affinity Complex, the albumin-binding linker present on the with-DAC form. It is a 29-amino-acid GHRH(1-29) analogue carrying amino acid substitutions for DPP-4 resistance, but without the extension that lets the with-DAC form ride circulating albumin for days. That missing linker is the whole basis of the dosing difference between the two forms. Sources describe no-DAC clearing from the body much faster, so common practice doses it daily rather than weekly.
CJC-1295 no DAC dosage: the common protocol
Clinic and vendor dosing guides most often describe 100-300 mcg by subcutaneous injection, once daily, five days a week (5 on, 2 off), typically before bed on an empty stomach. Cycles run 8-16 weeks with a 4-6 week break. This is common practice, not a dose any trial or regulator has established.
Common protocol
What is commonly used, not a dose established in trials. No regulator has set a dose for CJC-1295.
- Dose per administration
- 100-300 mcg
- How often
- once daily, 5 days a week (5 days on, 2 off), usually the no-DAC form
- Route
- Subcutaneous injection
- Cycle length
- 8-16 weeks
- Break between cycles
- 4-6 weeks
- Common vial size
- 5 mg
- Timing
- Before bed, on an empty stomach (at least two hours after the last meal).
- Commonly paired with
- Ipamorelin, 5-Amino-1MQ, AOD-9604, BPC-157
Sources describe the no-DAC form (mod GRF 1-29) dosed daily; the longer-acting with-DAC form is dosed roughly weekly at higher per-injection amounts, but that variant was not what the sourced daily protocols describe.
Plan a cycle in the protocol builder or work out injection volume in the dosage calculator.
The common CJC-1295 dose is 100-300 mcg, once daily, 5 days a week (5 days on, 2 off), usually the no-DAC form. From a 5 mg vial mixed with 2 mL of bacteriostatic water, 200 mcg is 8 units (0.08 mL) on a U-100 insulin syringe.
CJC-1295 5 mg vial: units per dose
Full 5 mg vial page: mixing, doses per vial, how long it lasts →
| Water added | Concentration | 1 unit = | 100 mcg | 200 mcg | 300 mcg |
|---|---|---|---|---|---|
| 1 mL | 5 mg/mL | 50 mcg | 2 units | 4 units | 6 units |
| 2 mL | 2.5 mg/mL | 25 mcg | 4 units | 8 units | 12 units |
| 3 mL | 1.67 mg/mL | 16.67 mcg | 6 units | 12 units | 18 units |
CJC-1295 10 mg vial: units per dose
Full 10 mg vial page: mixing, doses per vial, how long it lasts →
| Water added | Concentration | 1 unit = | 100 mcg | 200 mcg | 300 mcg |
|---|---|---|---|---|---|
| 1 mL | 10 mg/mL | 100 mcg | 1 unit | 2 units | 3 units |
| 2 mL | 5 mg/mL | 50 mcg | 2 units | 4 units | 6 units |
| 3 mL | 3.33 mg/mL | 33.33 mcg | 3 units | 6 units | 9 units |
All CJC-1295 vial sizes: 5 mg · 10 mg
Units are on a standard U-100 insulin syringe (100 units = 1 mL), rounded to the nearest half unit - half-unit marks are on 0.3 mL syringes. Water volumes are examples: more water means more units per dose, not more doses per vial. For any other vial or dose, use the dosage calculator.
How many 5 mg vials a cycle takes
| Scenario | Dose | Doses a week | Weeks | Total | 5 mg vials |
|---|---|---|---|---|---|
| Low end of the common protocol | 100 mcg | 5 | 8 | 4 mg | 1 |
| High end of the common protocol | 300 mcg | 5 | 16 | 24 mg | 5 |
Whole vials, rounded up. Plan a cycle with your own numbers in the protocol builder. Keep mixed vials cold and use them within the window in how long reconstituted peptides last; where to inject: subcutaneous injection sites.
For reconstitution and injection-volume arithmetic, the dosage calculator does the conversion. It does not choose a dose.
Side effects and who should not use it
There is no published human safety trial for either form of CJC-1295, so there is no clinical adverse-event rate to cite for the no-DAC form. Full detail, including user-reported effects described by two independent research-peptide sites, is on the main guide. No FDA-reviewed contraindication list exists for this form. Nobody should self-direct an unapproved research chemical around a current medical condition, medication or pregnancy.
Related
- CJC-1295 DAC dosage - the long-acting, weekly-dosed form
- CJC-1295: with DAC and without DAC, explained
- CJC-1295 dosage (with-DAC trial data)
- CJC-1295 and ipamorelin blend dosage
- Dosage calculator
Common questions
What is the usual CJC-1295 no DAC dose?
Clinic and vendor dosing guides most often describe 100-300 mcg by subcutaneous injection, once daily, five days a week with two days off. It is typically taken before bed on an empty stomach, for an 8-16 week cycle with a 4-6 week break. That is common practice reported by clinic and vendor pages, not a dose established by any trial or regulator.
What is the half-life of CJC-1295 no DAC?
No published human pharmacokinetic study I could find establishes it. The figure of roughly 30 minutes that circulates on vendor and community sites is not traceable to a primary study, so this page does not state it as fact.
Is CJC-1295 no DAC different from CJC-1295 with DAC?
Yes, in structure and in dosing. The with-DAC form carries an albumin-binding linker, has a published human half-life of 5.8-8.1 days, and is dosed roughly weekly. No DAC lacks that linker and is dosed daily under common practice. See the DAC-specific page for that separate protocol.